Fodor Eszter, Müller Veronika, Iványi Zsolt, Berki Tímea, Kuten Pella Olga, Hornyák István, Ambrus Mira, Sárkány Ágnes, Skázel Árpád, Madár Ágnes, Kardos Dorottya, Kemenesi Gábor, Földes Fanni, Nagy Sándor, Matusovits Andrea, János Nacsa, Tordai Attila, Jakab Ferenc, Lacza Zsombor
Orthosera Kft, Budapest, 1149, Hungary.
Univesity of Physical Education, Budapest, 1223, Hungary.
Infect Dis Ther. 2022 Feb;11(1):293-304. doi: 10.1007/s40121-021-00514-7. Epub 2021 Nov 24.
Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the early phase of the SARS-CoV2 pandemic through clinical studies using various protocols.
We present data from a cohort of 267 hospitalized severe COVID-19 patients who received CCP. No transfusion-related complications were reported, indicating the overall safety of CCP therapy.
Patients who eventually died from COVID-19 received CCP significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels.
We conclude that CCP transfusion is a safe and effective supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if applied as early as possible. We also observed that IL-6 may be a suitable laboratory parameter for patient selection and monitoring of CCP therapy effectiveness.
在新冠疫情早期，通过采用各种方案的临床研究，从康复的新冠患者（CCP）中采集的血浆已被用作一线治疗方法。
我们展示了一组267名接受CCP治疗的住院重症新冠患者的数据。未报告输血相关并发症，表明CCP治疗总体安全。
最终死于新冠的患者接受CCP治疗的时间明显更晚（入院后3.95天对5.22天），且白细胞介素6（IL-6）水平更高（28.9 pg/ml对102.5 pg/ml），高于存活患者。此外，无论疾病严重程度或结局如何，CCP输血均使患者的整体炎症状态显著降低，C反应蛋白、IL-6和铁蛋白水平降低证明了这一点。
我们得出结论，CCP输血是一种安全有效的辅助治疗方式，对于住院的新冠患者，如果尽早应用，预期结果会更好。我们还观察到，IL-6可能是用于患者选择和监测CCP治疗效果的合适实验室参数。
